Phase 1 Study of Pembrolizumab With A Vaccine for Metastatic NSCLC

Share this content:
Researchers are evaluating the safety and efficacy of pembrolizumab in combination with a synthetic long peptide vaccine among patients with non–small cell lung cancer.
Researchers are evaluating the safety and efficacy of pembrolizumab in combination with a synthetic long peptide vaccine among patients with non–small cell lung cancer.

Title: Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer1

Principal Investigators: Ramaswamy Govindan, MD, Washington University School of Medicine

Description: For this non-randomized phase 1 study, researchers are evaluating the safety and efficacy of pembrolizumab, a PD-1 inhibitor, in combination with a synthetic long peptide vaccine among patients with non–small cell lung cancer (NSCLC).

All included patients will have stage IV NSCLC stable after chemotherapy. The personalized vaccine will be developed after biopsy and will be administered several times throughout cycles 1 and 2 of pembrolizumab. All patients will receive pembrolizumab for up to 2 years.

The study's primary outcome is safety and feasibility; secondary outcomes include overall response rate, progression-free survival, and overall survival.

The estimated study enrollment is 20 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03166254.

Status: This study is open and recruiting patients as of November 29, 2017.

This study is sponsored by the Washington University School of Medicine.

Reference

  1. Clinicaltrials.gov. Combination of a personalized therapeutic anti-tumor vaccine with pembrolizumab in non-small cell lung cancer.  NCT03166254. https://clinicaltrials.gov/ct2/show/NCT03166254. Accessed November 29, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters